Publications

Detailed Information

Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans

DC Field Value Language
dc.contributor.authorPark, Eun-Kyung-
dc.contributor.authorChung, June-Key-
dc.contributor.authorLim, Il Han-
dc.contributor.authorPark, Do Joon-
dc.contributor.authorLee, Myung Chul-
dc.contributor.authorCho, Bo Youn-
dc.contributor.authorLee, Dong Soo-
dc.date.accessioned2012-05-24T01:19:43Z-
dc.date.available2012-05-24T01:19:43Z-
dc.date.issued2009-02-
dc.identifier.citationEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING; Vol.36 2; 172-179ko_KR
dc.identifier.issn1619-7070-
dc.identifier.urihttps://hdl.handle.net/10371/76374-
dc.description.abstractPurpose Serum Tg and I-131 WBS have been used to detect recurrent and metastatic thyroid cancers postoperatively. Tg is known to be more sensitive than I-131 WBS, and therefore, false-negative WBS cases with elevated Tg levels are frequently found. However, the clinical characteristics of false-negative Tg cases with positive WBS have not been clarified. Materials and methods The authors evaluated 824 postoperative patients with differentiated thyroid carcinoma who underwent post-ablation/therapy I-131 WBS. Tg negativity was defined as a Tg level of <= 2 ng/mL without TgAb under thyroid-stimulating hormone stimulation. Remission, recurrence, and metastasis were confirmed using pathologic or clinically findings. Results Fifty-two patients (6.3%) with functioning metastasis and negativity for TgAb were Tg-negative and posttherapy I-131 WBS-positive (TgN group), and 128 patients with functioning metastases were Tg positive and WBS positive (TgP group). The TgN group consisted of 45 cases of cervical/mediastinal lymph node metastases (86.5%) and seven cases of distant metastasis to lung or bone by follow-up WBS. The TgN group demonstrated significantly higher profiles of regional involvement than the TgP group (P<0.029). In 47 patients in the TgN group, metastatic uptake disappeared in 33, ameliorated in four, and persisted in ten during follow-up. Conclusions A significant number of differentiated thyroid cancer patients were Tg-/TgAb-negative despite a positive WBS finding. Cervical and mediastinal lymph nodes were predominant sites of metastasis in the TgN group. WBS should be undertaken routinely as a complementary modality to detect functioning recurrence and metastasis regardless of serum Tg results.ko_KR
dc.language.isoenko_KR
dc.publisherSPRINGERko_KR
dc.subjectDifferentiated thyroid carcinomako_KR
dc.subjectMetastasisko_KR
dc.subjectThyroglobulinko_KR
dc.subjectI-131 whole body scanko_KR
dc.subjectRecurrenceko_KR
dc.titleRecurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scansko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor박은경-
dc.contributor.AlternativeAuthor정준기-
dc.contributor.AlternativeAuthor임일한-
dc.contributor.AlternativeAuthor박도준-
dc.contributor.AlternativeAuthor이동수-
dc.contributor.AlternativeAuthor이명철-
dc.contributor.AlternativeAuthor조보연-
dc.identifier.doi10.1007/s00259-008-0912-0-
dc.citation.journaltitleEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING-
dc.description.citedreferencePazaitou-Panayiotou K, 2007, THYROID, V17, P1085, DOI 10.1089/thy.2007.0005-
dc.description.citedreferenceUrhan M, 2007, EUR J NUCL MED MOL I, V34, P1012, DOI 10.1007/s00259-006-0341-x-
dc.description.citedreferenceRault E, 2007, CANCER BIOTHER RADIO, V22, P423, DOI 10.1089/cbr.2006.323-
dc.description.citedreferenceSaghari M, 2006, NUCL MED COMMUN, V27, P567-
dc.description.citedreferencePacini F, 2006, EUR J ENDOCRINOL, V154, P787, DOI 10.1530/eje.1.02158-
dc.description.citedreferenceMa C, 2005, J NUCL MED, V46, P1473-
dc.description.citedreferenceIervasi A, 2004, J ENDOCRINOL, V182, P287-
dc.description.citedreferenceSchlumberger M, 2004, EUR J ENDOCRINOL, V150, P105-
dc.description.citedreferencePAGANO L, 2004, MINERVA ENDOCRINOL, V29, P161-
dc.description.citedreferencePellegriti G, 2003, CLIN ENDOCRINOL, V58, P556-
dc.description.citedreferenceMazzaferri EL, 2003, J CLIN ENDOCR METAB, V88, P1433, DOI 10.1210/jc.2002.021702-
dc.description.citedreferenceWada N, 2003, ANN SURG, V237, P399-
dc.description.citedreferenceBachelot A, 2002, THYROID, V12, P707-
dc.description.citedreferenceMorgenthaler NG, 2002, CLIN CHEM, V48, P1077-
dc.description.citedreferenceLarson SM, 2002, SEMIN ROENTGENOL, V37, P169, DOI 10.1053/sroe.2002.34210-
dc.description.citedreferenceAlzahrani AS, 2001, J CLIN ENDOCR METAB, V86, P5294-
dc.description.citedreferenceMazzaferri EL, 2000, THYROID, V10, P767-
dc.description.citedreferenceRonga G, 1999, EUR J NUCL MED, V26, P1448-
dc.description.citedreferenceSpencer CA, 1999, THYROID, V9, P435-
dc.description.citedreferenceMertens IJR, 1999, CLIN NUCL MED, V24, P346-
dc.description.citedreferenceSCHLUMBERGER MJ, 1999, J ENDOCRINOL INVES S, V22, P3-
dc.description.citedreferenceRUBELLO D, 1990, J ENDOCRINOL INVEST, V13, P737-
dc.description.citedreferenceBRENDEL AJ, 1990, EUR J NUCL MED, V16, P35-
dc.description.citedreferenceLEE BW, 1990, KOREAN J NUCL MED, V24, P80-
dc.description.citedreferenceSCHULZ R, 1989, EUR J CLIN INVEST, V19, P459-
dc.description.citedreferenceMULLERGARTNER HW, 1988, CANCER, V61, P976-
dc.description.citedreferenceGRANT S, 1984, CANCER, V54, P1625-
dc.description.citedreferenceMARIOTTI S, 1982, CLIN CHIM ACTA, V123, P347-
dc.description.citedreferenceSHAH DH, 1981, ACTA ENDOCRINOL-COP, V98, P222-
dc.description.citedreferenceNEMEC J, 1979, J NUCL MED, V20, P92-
dc.description.tc19-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share